- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01774630
Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2) (NiloPost-STIM)
Chronic myeloid leukemia (CML) is a hematopoietic neoplasm characterized by the reciprocal translocation t(9;22). The resulting oncoprotein, bcr-abl is an essential trigger for growth and survival of leukemic cells. In the past decade, the bcr-abl tyrosine kinase inhibitor (TKI) imatinib (IM or Glivec©) has been the standard of care for patients with CML, inducing durable responses. However, requiring continuing IM indefinitely and the ability of IM to eradicate the CML clone was uncertain.
In a small proportion of patients, IM can induce complete molecular response (CMR) defined by the disappearance of the bcr-abl transcript in conventional quantitative RT-PCR. The question whether or not these patients are cured and can discontinue drug therapy has been assessed by Mahon and coll, in the STIM study. He demonstrates that IM can be safely discontinued in patient with a CMR of at least 2 year duration and all patients who relapsed after IM discontinuation mainly did it in the first 6 months and responded to reintroduction of imatinib.
Nilotinib is a rationally designed second generation tyrosine kinase inhibitor with improved target specificity over imatinib. Its efficacy and safety in the treatment of patients who are resistant or intolerant to imatinib as well as patients with newly diagnosed CML-CP led to the registration in second and first line treatment of CML-CP patients. Nilotinib produces even faster and deeper responses with more occurrence of CMR than does Imatinib. Consequently, one can assume that a more potent drug such nilotinib could induce deeper and sustained CMR allowing longer period off treatment than IM.
The objective of this pilot trial is to assess if Nilotinib can rescue STIM patients in molecular relapse after IM discontinuation and to provide an estimation about duration of CMR after nilotinib discontinuation in 2nd line therapy among patients experiencing 2 years of stable CMR with nilotinib.
Study Overview
Status
Intervention / Treatment
Detailed Description
Patients with CML included in STIM trials, stopped their treatment by imatinib because the signal was not detectable. In case of reappearance of this transcript Bcr-Abl, the patient relapses. The trial Nilo Post STIM is suggested to the patient to assess if Nilotinib can rescue STIM patients in molecular relapse after IM discontinuation and to provide an estimation about duration of CMR after nilotinib discontinuation in 2nd line therapy among patients experiencing 2 years of stable CMR with nilotinib.
The treatment/strategy for this study:
Screening
- Inclusion/exclusion criteria
- CML history
- Confirm molecular relapse after discontinuation of imatinib (quantitative RT-PCR on two consecutive assessments from peripheral blood samples)
Treatment
• Nilotinib 300mg BID for 2 years
- Premature treatment discontinuation while on study: primary or secondary resistance progression to accelerated phase or blast crisis, AE (to be defined later).
- In case of unsatisfactory response: transcript stability or increase on two consecutive PCR: nilotinib blood monitoring, and nilotinib dose escalation up to 400mg BID will be proposed
- Discontinuation at 2 years for patients who resumed confirmed CMR
Follow-up while on treatment with nilotinib:
- Physical exam, basic laboratory parameters, monthly during the first 3 months then every 3 months.
- Centralized quantitative RT-PCR for Bcr-Abl monthly for 6 months then every 3 months for 24 months
- Follow AE management guidelines for nilotinib reduction/interruptions
Follow-up after nilotinib discontinuation
Patients in confirmed molecular relapse
- Physical exam, event collection, basic laboratory parameters (including glycemic and lipid profile) every 2 months during the first year then every 3 months
- Hematology and centralized quantitative RT-PCR monthly the first year then every 3 months for 12 months
- Patients without confirmed molecular relapse will take another treatment (dasatinib for example) and will stop their follow-up in the trial
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Angers, France, 49033
- CHU Angers
-
Bordeaux, France, 33076
- Institut Bergonie
-
Le Chesnay, France, 78157
- Centre Hospitalier de Versailles - Hôpital André Mignot - Service de Médecine B
-
Nice, France, 06202
- CHU de Nice, Service Hématologie Clinique
-
Pessac, France, 33604
- Hôpital Haut Lévêque, Service Hématologie
-
Pierre Benite, France, 69495
- Centre Hospitalier Lyon Sud, Service Hématologie
-
Pringy, France, 74374
- CH d'Annecy
-
Rennes, France, 35033
- Hopital Pontchaillou
-
Toulouse, France, 31059
- CHU de Toulouse, Service d'Hématologie
-
Valence, France, 26953
- Ch Valence
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female patients
- Patient participating to the STIM trials (including STIM, STIM2 et EURO-SKI) and with confirmed molecular relapse on two consecutive RQ PCR, after imatinib discontinuation
- Still in chronic phase
- Not yet treated for this relapse
- At least 18 years old (no upper age limit)
- SGOT and SGPT < 2.5 UNL
- Serum creatinin < 2 UNL
- No planned allogeneic stem cell transplantation
- Signed informed consent
- ECOG score 0 to 2
Exclusion Criteria:
- Pregnancy, lactation
- Prior or concurrent malignancy other than CML (exceptions to be mentioned)
- Serious uncontrolled cardiovascular disease
- Severe psychiatric/neurological disease (previous or ongoing)
- Ongoing treatment at risk for inducing "torsades de pointe"
- QTcF > 450ms despite correction of predisposing factors (i.e electrolytes…)
- Congenital long QTcF
- No health insurance coverage
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Nilotinib
300 mg/twice a day
|
300 mg/twice a day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Estimated survival rate of patients without molecular relapse 3 years after enrollment
Time Frame: Evaluation by RTq-PCR monthly the first year of treatment with nilotinib then every 3 months until 24 months, date of discontinuation of Nilotinib for patients in sustained complete molecular response (CMR). After discontinuation of Nilotinib patie
|
CMR is defined as >5 log reduction in Bcr-Abl and Abl levels and undetectable transcripts on quantitative RTq-PCR
|
Evaluation by RTq-PCR monthly the first year of treatment with nilotinib then every 3 months until 24 months, date of discontinuation of Nilotinib for patients in sustained complete molecular response (CMR). After discontinuation of Nilotinib patie
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate and kinetics of CMR while on treatment with nilotinib
Time Frame: at 6 and 12 months of treatment with nilotinib
|
Same definition of CMR as above
|
at 6 and 12 months of treatment with nilotinib
|
Duration of CMR while on treatment with nilotinib
Time Frame: Any time
|
Defined as the time from the date of first documented CMR to the date of first confirmed molecular relapse defined as positivity of Bcr-Abl transcripts in quantitative RT-PCR with a ratio of bcr-abl to Abl ≥ 10-5, as confirmed by a second analysis point at two successive assessments
|
Any time
|
Event free survival (EFS)
Time Frame: Any time
|
Events include loss of major molecular response (MMR) , loss of complete cytogenetic response (CCyR) loss of complete hematologic response (CHR), progression to accelerated phase and blst crisis (AP-BC), death whatever the cause, adverse-event leading to premature discontinuation of nilotinib
|
Any time
|
Safety tolerability of nilotinib and compliance
Time Frame: Any time
|
Haematological and non-haematological adverse events (AE) graded will be according to the NCI CTC AE v4.
Compliance will be estimated using the 4 items Morisky scale
|
Any time
|
Duration of CMR after nilotinib discontinuation
Time Frame: Measured from the start of nilotinib discontinuation to the date of first confirmed molecular relapse as defined above
|
Measured from the start of nilotinib discontinuation to the date of first confirmed molecular relapse as defined above
|
|
Event free survival (EFS)
Time Frame: Overall and after nilotinib discontinuation
|
Same events as for EFS described above
|
Overall and after nilotinib discontinuation
|
Predictive factors of maintained CMR after nilotinib discontinuation: sex, Sokal risk score at diagnosis, duration of previous treatment with imatinib, CMR duration before and after discontinuation of imatinib
Time Frame: After discontinuation of nilotinib
|
Parameters will be recorded before and after both sequences of treatment imatinib and nilotinib
|
After discontinuation of nilotinib
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Viviane DUBRUILLE, Nantes University Hospital
- Study Chair: Gabriel ETIENNE, University Hospital Bordeaux, France
- Study Chair: Franck NICOLINI, Hospices Civils de LYON
- Study Chair: Delphine REA, APHP, St Louis Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHUBX 2012/18
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leukemia, Myelogenous, Chronic, BCR-ABL Positive
-
Versailles HospitalUniversity Hospital, Bordeaux; Maisonneuve-Rosemont HospitalCompletedChronic Myelogenous Leukemia, BCR/ABL PositiveFrance, Canada
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous LeukemiaUnited States
-
PfizerCompletedLeukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) PositiveFrance, United States, Canada, Spain, Czechia, Singapore, Thailand, Denmark, Norway, Korea, Republic of, Finland, Hungary, Sweden, Netherlands, Italy, Germany, Ukraine, South Africa, Taiwan, Australia, Belgium, Israel, Mexico, Poland, S... and more
-
Emory UniversityTerminatedRecurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Chronic Myelogenous Leukemia, BCR-ABL1 PositiveUnited States
-
Mansoura UniversityCompletedCML, Chronic Phase | Chronic Myelogenous Leukemia, BCR-ABL PositiveEgypt
-
University of Milano BicoccaIRCCS San RaffaeleCompletedLeukemia | BCR-ABL Positive | Myelogenous | ChronicItaly
-
National Cancer Institute (NCI)CompletedChronic Phase Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 PositiveUnited States
-
National Cancer Institute (NCI)CompletedChronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 PositiveUnited States
-
National Cancer Institute (NCI)CompletedChildhood Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 PositiveUnited States
-
National Research Center for Hematology, RussiaActive, not recruitingChronic Myeloid Leukemia | Chronic Myeloid Leukemia in Remission | BCR-ABL Positive Chronic Myelogenous LeukemiaRussian Federation
Clinical Trials on Nilotinib
-
Niguarda HospitalCompletedLeukemia, Myeloid, Chronic-PhaseItaly
-
Novartis PharmaceuticalsTerminatedPulmonary Arterial HypertensionSwitzerland, United States, Germany, Singapore, Korea, Republic of, Canada
-
Georgetown UniversityUnknownParkinson Disease | Parkinsons Disease With DementiaUnited States
-
XSpray MicroparticlesCompleted
-
Shenzhen Second People's HospitalDongguan People's Hospital; Zhongshan People's Hospital, Guangdong, China; The... and other collaboratorsRecruitingChronic Myeloid Leukemia, Chronic Phase | NilotinibChina
-
Andrew J. Wagner, MD, PhDMassachusetts General Hospital; Novartis; Brigham and Women's HospitalActive, not recruitingTenosynovial Giant Cell Tumor | Pigmented Villonodular Synovitis | Diffuse-type Giant Cell TumorUnited States
-
Novartis PharmaceuticalsNo longer availableHypereosinophilic Syndrome (HES)
-
KeifeRx, LLCWorldwide Clinical Trials; Life Molecular Imaging GmbH; Sun Pharmaceuticals Industries...Not yet recruiting
-
Novartis PharmaceuticalsNo longer availableAcute Lymphoblastic Leukemia (ALL)
-
Novartis PharmaceuticalsCompleted